HCV Treatment
AASLD 2011: Sustained Response is Durable among Hepatitis C Patients Treated with Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 03 January 2012 00:00
- Written by Liz Highleyman
Almost all chronic hepatitis C patients who achieved sustained virological response (SVR) using the recently approved HCV protease inhibitor telaprevir (Incivek) plus pegylated interferon and ribavirin continued to have undetectable viral load nearly 2 years later, according to data presented at the recent American Association for the Study of Liver Disease (AASLD) Liver Meeting in San Francisco.
PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for pegylated interferon alfa-2b (brand name PegIntron) to incorporate information about its use with the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek), as well as use by people with psychiatric conditions.
Top 10 HIV and Hepatitis Stories of 2011
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
In our last issue for 2011, HIVandHepatitis.com reviews some the year's major news highlights. HIV prevention garnered the most headlines, with studies showing that antiretroviral therapy (ART) prevents transmission and pre-exposure prophylaxis (PrEP) works -- at least for some people some of the time. On the hepatitis C front, the first new direct-acting antiviral drugs were approved, ushering in a new era of more effective treatment.
AASLD 2011: Fever Signals Responsiveness to Pegylated Interferon for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
People who have an increase in body temperature soon after starting interferon-based therapy for chronic hepatitis C virus (HCV) infection are more likely to experience early virological response, according to a presentation at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 December 2011 00:00
- Written by Transgene
Transgene's recombinant poxvirus therapeutic hepatitis C virus (HCV) vaccine, TG4040, demonstrated good tolerability and increased the likelihood of viral suppression at 12 weeks when administered with pegylated interferon plus ribavirin, according to data from an international Phase 2 clinical trial reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in San Francisco. 
Web Design and Development by